-+ 0.00%
-+ 0.00%
-+ 0.00%

Kura Oncology, Kyowa Kirin dose first patient in Japan Phase 2 ziftomenib trial

PUBT·04/27/2026 18:47:29
Listen to the news
Kura Oncology, Kyowa Kirin dose first patient in Japan Phase 2 ziftomenib trial
  • Kyowa Kirin started a Japanese Phase 2 registration-directed trial of Kura Oncology-partnered ziftomenib in relapsed or refractory NPM1-mutated acute myeloid leukemia, with first patient dosed.
  • Trial results have not been presented; Kyowa Kirin plans a Japan regulatory filing once study completes.
  • Study will evaluate whether once-daily oral ziftomenib can deliver clinically meaningful remissions, aiming to expand access beyond US market.
  • Ziftomenib, sold as KOMZIFTI, entered US market in November 2025 for adults with relapsed or refractory NPM1-mutated AML lacking satisfactory alternatives.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kura Oncology Inc. published the original content used to generate this news brief on April 24, 2026, and is solely responsible for the information contained therein.